Peroxisome proliferator-activated receptor δ confers resistance to peroxisome proliferator-activated receptor γ-induced apoptosis in colorectal cancer cells (original) (raw)

• Altieri DC . (2003). Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3: 46–54.
  Article CAS Google Scholar
• Asanuma K, Moriai R, Yajima T, Yagihashi A, Yamada M, Kobayashi D et al. (2000). Survivin as a radioresistance factor in pancreatic cancer. Jpn J Cancer Res 91: 1204–1209.
  Article CAS Google Scholar
• Burstein HJ, Demetri GD, Mueller E, Sarraf P, Spiegelman BM, Winer EP . (2003). Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res Treat 79: 391–397.
  Article CAS Google Scholar
• Cellai I, Benvenuti S, Luciani P, Galli A, Ceni E, Simi L et al. (2006). Antineoplastic effects of rosiglitazone and PPARgamma transactivation in neuroblastoma cells. Br J Cancer 95: 879–888.
  Article CAS Google Scholar
• Di-Poi N, Michalik L, Tan NS, Desvergne B, Wahli W . (2003). The anti-apoptotic role of PPARbeta contributes to efficient skin wound healing. J Steroid Biochem Mol Biol 85: 257–265.
  Article CAS Google Scholar
• Di-Poi N, Tan NS, Michalik L, Wahli W, Desvergne B . (2002). Antiapoptotic role of PPARbeta in keratinocytes via transcriptional control of the Akt1 signaling pathway. Mol Cell 10: 721–733.
  Article CAS Google Scholar
• Farrow B, Evers BM . (2003). Activation of PPARgamma increases PTEN expression in pancreatic cancer cells. Biochem Biophys Res Commun 301: 50–53.
  Article CAS Google Scholar
• Fukuda S, Foster RG, Porter SB, Pelus LM . (2002). The antiapoptosis protein survivin is associated with cell cycle entry of normal cord blood CD34(+) cells and modulates cell cycle and proliferation of mouse hematopoietic progenitor cells. Blood 100: 2463–2471.
  Article CAS Google Scholar
• Girnun GD, Smith WM, Drori S, Sarraf P, Mueller E, Eng C et al. (2002). APC-dependent suppression of colon carcinogenesis by PPARgamma. Proc Natl Acad Sci USA 99: 13771–13776.
  Article CAS Google Scholar
• Gupta RA, Brockman JA, Sarraf P, Willson TM, DuBois RN . (2001). Target genes of peroxisome proliferator-activated receptor gamma in colorectal cancer cells. J Biol Chem 276: 29681–29687.
  Article CAS Google Scholar
• Gupta RA, Wang D, Katkuri S, Wang H, Dey SK, DuBois RN . (2004). Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-delta accelerates intestinal adenoma growth. Nat Med 10: 245–247.
  Article CAS Google Scholar
• Han S, Roman J . (2006). Rosiglitazone suppresses human lung carcinoma cell growth through PPARgamma-dependent and PPARgamma-independent signal pathways. Mol Cancer Ther 5: 430–437.
  Article CAS Google Scholar
• Hao CM, Redha R, Morrow J, Breyer MD . (2002). Peroxisome proliferator-activated receptor delta activation promotes cell survival following hypertonic stress. J Biol Chem 277: 21341–21345.
  Article CAS Google Scholar
• Harman FS, Nicol CJ, Marin HE, Ward JM, Gonzalez FJ, Peters JM . (2004). Peroxisome proliferator-activated receptor-delta attenuates colon carcinogenesis. Nat Med 10: 481–483.
  Article CAS Google Scholar
• He TC, Chan TA, Vogelstein B, Kinzler KW . (1999). PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 99: 335–345.
  Article CAS Google Scholar
• Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M . (2002). Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 277: 3247–3257.
  Article CAS Google Scholar
• Kato Y, Ying H, Zhao L, Furuya F, Araki O, Willingham MC et al. (2006). PPARgamma insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factor-kappaB signaling pathway. Oncogene 25: 2736–2747.
  Article CAS Google Scholar
• Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N . (1998). Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 58: 5071–5074.
  CAS PubMed Google Scholar
• Kim EJ, Park KS, Chung SY, Sheen YY, Moon DC, Song YS et al. (2003). Peroxisome proliferator-activated receptor-gamma activator 15-deoxy-Delta12,14-prostaglandin J2 inhibits neuroblastoma cell growth through induction of apoptosis: association with extracellular signal-regulated kinase signal pathway. J Pharmacol Exp Ther 307: 505–517.
  Article CAS Google Scholar
• Kulke MH, Demetri GD, Sharpless NE, Ryan DP, Shivdasani R, Clark JS et al. (2002). A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. Cancer J 8: 395–399.
  Article Google Scholar
• Kuo PC, Liu HF, Chao JI . (2004). Survivin and p53 modulate quercetin-induced cell growth inhibition and apoptosis in human lung carcinoma cells. J Biol Chem 279: 55875–55885.
  Article CAS Google Scholar
• Lefebvre AM, Chen I, Desreumaux P, Najib J, Fruchart JC, Geboes K et al. (1998). Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med 4: 1053–1057.
  Article CAS Google Scholar
• Li M, Lee TW, Mok TS, Warner TD, Yim AP, Chen GG . (2005). Activation of peroxisome proliferator-activated receptor-gamma by troglitazone (TGZ) inhibits human lung cell growth. J Cell Biochem 96: 760–774.
  Article CAS Google Scholar
• Nadra K, Anghel SI, Joye E, Tan NS, Basu-Modak S, Trono D et al. (2006). Differentiation of trophoblast giant cells and their metabolic functions are dependent on peroxisome proliferator-activated receptor beta/delta. Mol Cell Biol 26: 3266–3281.
  Article CAS Google Scholar
• O'Connor DS, Wall NR, Porter AC, Altieri DC . (2002). A p34(cdc2) survival checkpoint in cancer. Cancer Cell 2: 43–54.
  Article CAS Google Scholar
• Olie RA, Simoes-Wust AP, Baumann B, Leech SH, Fabbro D, Stahel RA et al. (2000). A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 60: 2805–2809.
  CAS Google Scholar
• Osawa E, Nakajima A, Wada K, Ishimine S, Fujisawa N, Kawamori T et al. (2003). Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology 124: 361–367.
  Article CAS Google Scholar
• Panigrahy D, Huang S, Kieran MW, Kaipainen A . (2005). PPARgamma as a therapeutic target for tumor angiogenesis and metastasis. Cancer Biol Ther 4: 687–693.
  Article CAS Google Scholar
• Park BH, Vogelstein B, Kinzler KW . (2001). Genetic disruption of PPARdelta decreases the tumorigenicity of human colon cancer cells. Proc Natl Acad Sci USA 98: 2598–2603.
  Article CAS Google Scholar
• Peters JM, Lee SS, Li W, Ward JM, Gavrilova O, Everett C et al. (2000). Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta). Mol Cell Biol 20: 5119–5128.
  Article CAS Google Scholar
• Pino MV, Kelley MF, Jayyosi Z . (2004). Promotion of colon tumors in C57BL/6J-APC(min)/+ mice by thiazolidinedione PPARgamma agonists and a structurally unrelated PPARgamma agonist. Toxicol Pathol 32: 58–63.
  Article CAS Google Scholar
• Saez E, Tontonoz P, Nelson MC, Alvarez JG, Ming UT, Baird SM et al. (1998). Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat Med 4: 1058–1061.
  Article CAS Google Scholar
• Salvesen GS, Duckett CS . (2002). IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 3: 401–410.
  Article CAS Google Scholar
• Sarela AI, Scott N, Ramsdale J, Markham AF, Guillou PJ . (2001). Immunohistochemical detection of the anti-apoptosis protein, survivin, predicts survival after curative resection of stage II colorectal carcinomas. Ann Surg Oncol 8: 305–310.
  Article CAS Google Scholar
• Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB et al. (1998). Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 4: 1046–1052.
  Article CAS Google Scholar
• Takayama O, Yamamoto H, Damdinsuren B, Sugita Y, Ngan CY, Xu X et al. (2006). Expression of PPARdelta in multistage carcinogenesis of the colorectum: implications of malignant cancer morphology. Br J Cancer 95: 889–895.
  Article CAS Google Scholar
• Teresi RE, Shaiu CW, Chen CS, Chatterjee VK, Waite KA, Eng C . (2006). Increased PTEN expression due to transcriptional activation of PPARgamma by Lovastatin and Rosiglitazone. Int J Cancer 118: 2390–2398.
  Article CAS Google Scholar
• Ueda Y, Wang S, Dumont N, Yi JY, Koh Y, Arteaga CL . (2004). Overexpression of HER2 (erbB2) in human breast epithelial cells unmasks transforming growth factor beta-induced cell motility. J Biol Chem 279: 24505–24513.
  Article CAS Google Scholar
• Wang D, Buchanan FG, Wang H, Dey SK, DuBois RN . (2005). Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein kinase cascade. Cancer Res 65: 1822–1829.
  Article CAS Google Scholar
• Wang D, Wang H, Brown J, Daikoku T, Ning W, Shi Q et al. (2006a). CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med 203: 941–951.
  Article CAS Google Scholar
• Wang D, Wang H, Guo Y, Ning W, Katkuri S, Wahli W et al. (2006b). Crosstalk between peroxisome proliferator-activated receptor delta and VEGF stimulates cancer progression. Proc Natl Acad Sci USA 103: 19069–19074.
  Article CAS Google Scholar
• Wang D, Wang H, Shi Q, Katkuri S, Walhi W, Desvergne B et al. (2004). Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell 6: 285–295.
  Article CAS Google Scholar
• Williams CW, Luongo C, Radhika A, Zhang T, Lamps LW, Nanney LB et al. (1996). Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology 111: 1134–1140.
  Article CAS Google Scholar
• Yin Y, Russell RG, Dettin LE, Bai R, Wei ZL, Kozikowski AP et al. (2005). Peroxisome proliferator-activated receptor delta and gamma agonists differentially alter tumor differentiation and progression during mammary carcinogenesis. Cancer Res 65: 3950–3957.
  Article CAS Google Scholar
• Zaffaroni N, Daidone MG . (2002). Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Resist Updat 5: 65–72.
  Article CAS Google Scholar
• Zhang T, Otevrel T, Gao Z, Gao Z, Ehrlich SM, Fields JZ et al. (2001). Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res 61: 8664–8667.
  CAS Google Scholar
• Zhao J, Tenev T, Martins LM, Downward J, Lemoine NR . (2000). The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. J Cell Sci 113 (Part 23): 4363–4371.
  CAS Google Scholar
• Zuo X, Peng Z, Moussalli MJ, Morris JS, Broaddus RR, Fischer SM et al. (2009). Targeted genetic disruption of peroxisome proliferator-activated receptor-delta and colonic tumorigenesis. J Natl Cancer Inst 101: 762–767.
  Article CAS Google Scholar